Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: The look AHEAD study

Journal of Lipid Research

Volumn 53, Issue 12, 2012, Pages 2726-2733

  Belalcazar, L Maria ^a   Lang, Wei ^b   Haffner, Steven M ^c   Hoogeveen, Ron C ^d   Pi Sunyer, F Xavier ^e   Schwenke, Dawn C ^f   Balasubramanyam, Ashok ^d   Tracy, Russell P ^g   Kriska, Andrea P ^h   Ballantyne, Christie M ^d,i  

^a University of Texas Medical Branch School of Medicine   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f ARIZONA STATE UNIVERSITY   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Adipose tissue; Diabetes; High density lipoprotein; Lifestyle intervention; Obesity; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BEHAVIOR CHANGE; BODY WEIGHT; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEMOGRAPHY; DIABETES EDUCATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FEMALE; FITNESS; GLYCEMIC CONTROL; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; WALKING; WEIGHT REDUCTION;

ADIPONECTIN; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; WEIGHT LOSS;

EID: 84869024719     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M030213     Document Type: Article

References (30)

1. Franco, O. H., E. W. Steyerberg, F. B. Hu, J. Mackenbach, and W. Nusselder. 2007. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 167: 1145-1151.
2. Xu, H., G. T. Barnes, Q. Yang, G. Tan, D. Yang, C. J. Chou, J. Sole, A. Nichols, J. S. Ross, L. A. Tartaglia, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830.
3. Kim, J. Y., E. van de Wall, M. Laplante, A. Azzara, M. E. Trujillo, S. M. Hofmann, T. Schraw, J. L. Durand, H. Li, G. Li, et al. 2007. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117: 2621-2637.
4. Chung, S., J. K. Sawyer, A. K. Gebre, N. Maeda, and J. S. Parks. 2011. Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation. 124: 1663-1672.
5. Samad, F., K. D. Hester, G. Yang, Y. A. Hannun, and J. Bielawski. 2006. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes. 55: 2579-2587.
6. Basu, R., U. B. Pajvani, R. A. Rizza, and P. E. Scherer. 2007. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes. 56: 2174-2177.
7. Cnop, M., P. J. Havel, K. M. Utzschneider, D. B. Carr, M. K. Sinha, E. J. Boyko, B. M. Retzlaff, R. H. Knopp, J. D. Brunzell, and S. E. Kahn. 2003. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 46: 459-469.
8. Schulze, M. B., I. Shai, E. B. Rimm, T. Li, N. Rifai, and F. B. Hu. 2005. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes. 54: 534-539.
9. Mantzoros, C. S., T. Li, J. E. Manson, J. B. Meigs, and F. B. Hu. 2005. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J. Clin. Endocrinol. Metab. 90: 4542-4548.
10. Tsao, T. S., E. Tomas, H. E. Murrey, C. Hug, D. H. Lee, N. B. Ruderman, J. E. Heuser, and H. F. Lodish. 2003. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J. Biol. Chem. 278: 50810-50817.
11. Esposito, K., A. Pontillo, C. Di Palo, G. Giugliano, M. Masella, R. Marfella, and D. Giugliano. 2003. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J. Am. Med. Assoc. 289: 1799-1804.
12. Mather, K. J., T. Funahashi, Y. Matsuzawa, S. Edelstein, G. A. Bray, S. E. Kahn, J. Crandall, S. Marcovina, B. Goldstein, and R. Goldberg. 2008. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes. 57: 980-986.
13. Baratta, R., S. Amato, C. Degano, M. G. Farina, G. Patane, R. Vigneri, and L. Frittitta. 2004. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J. Clin. Endocrinol. Metab. 89: 2665-2671.
14. Lara-Castro, C., N. Luo, P. Wallace, R. L. Klein, and W. T. Garvey. 2006. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 55: 249-259.
15. Look AHEAD Research Group, T. A. Wadden, D. S. West, L. Delahanty, J. Jakicic, J. Rejeski, D. Williamson, R. I. Berkowitz, D. E. Kelley, C. Tomchee, et al. 2006. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 14: 737-752.
16. Zhu, N., J. S. Pankow, C. M. Ballantyne, D. Couper, R. C. Hoogeveen, M. Pereira, B. B. Duncan, and M. I. Schmidt. 2010. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J. Clin. Endocrinol. Metab. 95: 5097-5104.
17. Pi-Sunyer, X., G. Blackburn, F. L. Brancati, G. A. Bray, R. Bright, J. M. Clark, J. M. Curtis, M. A. Espeland, J. P. Foreyt, et al. 2007. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care. 30: 1374-1383.
18. Williamson, D. A., J. Rejeski, W. Lang, B. Van Dorsten, A. N. Fabricatore, K. Toledo, and Look AHEAD Research Group. 2009. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch. Intern. Med. 169: 163-171.
19. Baron, R. M., and D. A. Kenny. 1986. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 51: 1173-1182.
20. Sobel, M. E. 1982. Asymptotic confidence intervals for indirect effects in structural equation models. In Sociological Methodology. S. Leinhardt, editor. American Sociological Association, Washington, DC. 290-312.
21. Look AHEAD Research Group, G. Bray, E. Gregg, S. Haffner, X. F. Pi-Sunyer, L. E. WagenKnecht, M. Walkup, and R. Wing. 2006. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diab. Vasc. Dis. Res. 3: 202-215.
22. Oku, H., F. Matsuura, M. Koseki, J. C. Sandoval, M. Yuasa-Kawase, K. Tsubakio-Yamamoto, D. Masuda, N. Maeda, T. Ohama, M. Ishigami, et al. 2007. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett. 581: 5029-5033.
23. Zhang, Y., F. C. McGillicuddy, C. C. Hinkle, S. O'Neill, J. M. Glick, G. H. Rothblat, and M. P. Reilly. 2010. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation. 121: 1347-1355.
24. Belalcazar, L. M., and C. M. Ballantyne. 1998. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog. Cardiovasc. Dis. 41: 151-174.
25. Wang, Y., K. S. Lam, M. H. Yau, and A. Xu. 2008. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem. J. 409: 623-633.
26. Pajvani, U. B., M. Hawkins, T. P. Combs, M. W. Rajala, T. Doebber, J. P. Berger, J. A. Wagner, M. Wu, A. Knopps, A. H. Xiang, et al. 2004. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 279: 12152-12162.
27. Ng, T. W., G. F. Watts, P. H. Barrett, K. A. Rye, and D. C. Chan. 2007. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care. 30: 2945-2950.
28. Yamauchi, T., Y. Nio, T. Maki, M. Kobayashi, T. Takazawa, M. Iwabu, M. Okada-Iwabu, S. Kawamoto, N. Kubota, T. Kubota, et al. 2007. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13: 332-339
29. Holland, W. L., R. A. Miller, Z. V. Wang, K. Sun, B. M. Barth, H. H. Bui, K. E. Davis, B. T. Bikman, N. Halberg, J. M. Rutkowski, et al. 2011. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17: 55-63.
30. Christoffersen, C., H. Obinata, S. B. Kumaraswamy, S. Galvani, J. Ahnstrom, M. Sevvana, C. Egerer-Sieber, Y. A. Muller, T. Hla, L. B. Nielsen, et al. 2011. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. USA. 108: 9613-9618.